Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 391 to 405 of 734 results for diabet*

  1. Clinical features for distinguishing between type 1 diabetes and other types of diabetes: What are the best clinical features or combination of features for distinguishing between type 1 diabetes and other types of diabetes?

    type 1 diabetes and other types of diabetes: What are the best clinical features or combination of features for...

    Research recommendation
    Published
    11 April 2022

  2. What are the most effective and cost effective ways of developing, implementing and assessing tailored and culturally appropriate community-level interventions to prevent type 2 diabetes among people at high risk? This includes people from a range of black and minority ethnic groups and those from lower socioeconomic communities.

    culturally appropriate community-level interventions to prevent type 2 diabetes among people at high risk? This includes people from a...

    Research recommendation
    Published
    9 June 2015

  3. Single cut-off points: What are the risks and benefits of developing single-figure cut-off points on BMI and waist-to-height ratio for black, Asian and other minority ethnic groups to help prevent diabetes and other conditions?

    ratio for black, Asian and other minority ethnic groups to help prevent diabetes and other conditions? Any explanatory notes(if...

    Research recommendation
    Published
    30 September 2022

  4. What are the roles of insulin pump therapy (continuous subcutaneous insulin infusion) and continuous glucose monitoring in helping women with diabetes to achieve blood glucose targets before pregnancy?

    with diabetes to achieve blood glucose targets before pregnancy? Any explanatory notes(if applicable) Babies born to women with...

    Research recommendation
    Published
    9 June 2015

  5. Non-invasive tests for diagnosing NAFLD in adults:- Which non-invasive tests are most accurate and cost-effective in identifying non-alcoholic fatty liver disease (NAFLD) in adults with risk factors, type 2 diabetes and metabolic syndrome?

    non-alcoholic fatty liver disease (NAFLD) in adults with risk factors, type 2 diabetes and metabolic syndrome? Any explanatory notes(if...

    Research recommendation
    Published
    24 August 2016

  6. Methotrexate and risk of hepatotoxicity:- What is the impact of methotrexate compared with other approaches to care (for example other systemic non-biological or biological treatments) on risk of significant liver disease in people with psoriasis and do risk factors such as obesity, alcohol use or diabetes alter this risk?

    people with psoriasis and do risk factors such as obesity, alcohol use or diabetes alter this risk? Any explanatory notes(if applicable)...

    Research recommendation
    Published
    9 June 2015

  7. Monitoring for cystic-fibrosis-related diabetes:- What is the most effective strategy to detect diabetes in people with cystic fibrosis?

    Monitoring for cystic-fibrosis-related diabetes:- What is the most effective strategy to detect diabetes in people with...

    Research recommendation
    Published
    18 October 2018

  8. NICE recommends that further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with diabetic macular oedema should be conducted.

    clinical and cost effectiveness of ranibizumab and bevacizumab in people with diabetic macular oedema should be conducted. Any...

    Research recommendation
    Published
    9 June 2015

  9. Dapagliflozin for treating chronic kidney disease (TA1075)

    Evidence-based recommendations on dapagliflozin for treating chronic kidney disease in adults.

    Technology appraisal guidance
    Published
    2 July 2025
    View recommendations

    Sections for TA1075

  10. Liraglutide for managing overweight and obesity (TA664)

    Evidence-based recommendations on liraglutide (Saxenda) for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults.

    Technology appraisal guidance
    Published
    9 December 2020
    View recommendations

    Sections for TA664

  11. Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over (TA1093)

    Evidence-based recommendations on idebenone (Raxone) for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over.

    Technology appraisal guidance
    Published
    28 August 2025

    Sections for TA1093

  12. Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis (TA1096)

    Evidence-based recommendations on benralizumab (Fasenra) for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis in adults.

    Technology appraisal guidance
    Published
    3 September 2025
    View recommendations

    Sections for TA1096

  13. Tirzepatide for managing overweight and obesity (TA1026)

    Evidence-based recommendations on tirzepatide (Mounjaro) for managing overweight and obesity in adults.

    Technology appraisal guidance
    Last updated
    1 September 2025
    View recommendations

    Sections for TA1026

  14. Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)

    Evidence-based recommendations on guselkumab (Tremfya) for active psoriatic arthritis after inadequate response to DMARDs in adults.

    Technology appraisal guidance
    Published
    10 August 2022
    View recommendations

    Sections for TA815

  15. Belzutifan for treating tumours associated with von Hippel-Lindau disease (TA1011)

    Evidence-based recommendations on belzutifan (Welireg) for treating tumours associated with von Hippel-Lindau disease in adults.

    Technology appraisal guidance
    Published
    16 October 2024
    View recommendations

    Sections for TA1011